MBI Ordered to Cease Manufacturing and Distributing Products
December 2, 2005
FDA has ordered MBI Distributing, also known as Molecular Biologics, to cease manufacturing and distributing all drug products. The company has violated current good manufacturing practices (CGMPs) for their eye drops and has insufficient quality control procedures to verify product sterility. In addition, two eye drop products, Visitein and Clarity Vision for Life, are unapproved drugs, which are marketed as homeopathic antioxidant supplements.
The company has also violated labeling requirements for their pain relievers. Warning information is insufficient and may promote unsafe product use.
Pharmacies should check their inventory for eye drops manufactured by MBI. Pharmacies, consumers, and health care providers should dispose of the following products:
- Bright Eyes
- Bright Eyes II
- Can-C eye drop brands
- Clarity Vision for Life
Pharmacies should also check their inventory for pain relievers manufactured by MBI. Pharmacies, consumers, and health care providers should dispose of the following products:
Additional information is available at the following links:
- MedWatch Alert:
- FDA press release:
December 2, 2005; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.